Figures
Abstract
Objectives
We hypothesised that assessment of plasma C-terminal pro-endothelin-1 (CT-proET-1), a stable endothelin-1 precursor fragment, is of prognostic value in patients with chronic heart failure (CHF), beyond other prognosticators, including N-terminal pro-B-type natriuretic peptide (NT-proBNP).
Methods
We examined 491 patients with systolic CHF (age: 63±11 years, 91% men, New York Heart Association [NYHA] class [I/II/III/IV]: 9%/45%/38%/8%, 69% ischemic etiology). Plasma CT-proET-1 was detected using a chemiluminescence immunoassay.
Results
Increasing CT-proET-1 was a predictor of increased cardiovascular mortality at 12-months of follow-up (standardized hazard ratio 1.42, 95% confidence interval [CI] 1.04–1.95, p = 0.03) after adjusting for NT-proBNP, left ventricular ejection fraction (LVEF), age, creatinine, NYHA class. In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for CT-proET-1 and NT-proBNP (p = 0.40). Both NT-proBNP and CT-proET-1 added prognostic value to a base model that included LVEF, age, creatinine, and NYHA class. Adding CT-proET-1 to the base model had stronger prognostic power (p<0.01) than adding NT-proBNP (p<0.01). Adding CT-proET-1 to NT-proBNP in this model yielded further prognostic information (p = 0.02).
Citation: Jankowska EA, Filippatos GS, von Haehling S, Papassotiriou J, Morgenthaler NG, Cicoira M, et al. (2011) Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1. PLoS ONE 6(1): e14506. https://doi.org/10.1371/journal.pone.0014506
Editor: Gian Paolo Fadini, University of Padova, Italy
Received: July 19, 2010; Accepted: December 15, 2010; Published: January 17, 2011
Copyright: © 2011 Jankowska et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Stephan von Haehling has received speaker's fees from B.R.A.H.M.S AG for giving presentations on biomarkers produced and marketed by B.R.A.H.M.S. AG. Nils G. Morgenthaler, Jana Papassotiriou, Joachim Struck, Oliver Hartmann, and Andreas Bergmann are employed by B.R.A.H.M.S. AG, which is a biotech company that developed the CT-proET-1 assay. The funder B.R.A.H.M.S. AG was involved in data collection and analysis and reviewed the manuscript before submission. Andreas Bergmann is a member of the board of directors and shareholder of B.R.A.H.M.S. AG. Stefan D. Anker has received consultant honoraria from B.R.A.H.M.S. AG.
Competing interests: Stephan von Haehling has received speaker's fees from B.R.A.H.M.S. AG for giving presentations on biomarkers produced and marketed by B.R.A.H.M.S. AG. Nils G. Morgenthaler, Jana Papassotiriou, Joachim Struck, Oliver Hartmann, and Andreas Bergmann are employed by B.R.A.H.M.S. AG, which is a biotech company that developed the CT-proET-1 assay. The funder B.R.A.H.M.S. AG was involved in data collection and analysis and reviewed the manuscript before submission. Andreas Bergmann is a member of the board of directors and shareholder of B.R.A.H.M.S. AG. Stefan D. Anker has received consultant honoraria from B.R.A.H.M.S. AG. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. All other authors report no conflict of interest.
Introduction
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide secreted mainly by endothelial cells [1], [2]. It is also produced by other cells associated with cardiovascular homeostasis such as smooth muscle cells, cardiomyocytes, and macrophages [1], [2]. Activation of the ET-1 system is involved in the pathogenesis of several cardiovascular diseases, including hypertension, coronary artery disease, and chronic heart failure (CHF) [1], [2].
It is presumed that the assessment of circulating ET-1 might represent a marker of disease progression and prognosis in patients with CHF [3], [4]. This issue is of a particular clinical importance, as the prognostic evaluation in this group of patients still remains a challenge. The precise identification of patients with CHF and the highest risk of death and/or disease progression would enable clinicians to intensify both pharmacotherapy and device-based management early in the course of the disease. In recent years, a huge emphasis has been put on neurohumoral mediators as potential prognostic markers in patients with CHF [5], [6]. Over the last several years, circulating natriuretic peptides have become widely accepted as diagnostic and prognostic measures in all stages of CHF [5], [6], but also other complementary neurohumoral markers are intensively studied in this field [7], [8].
Increased circulating levels of ET-1 have been demonstrated in patients with CHF [3], [4], [9], [10], [11], but its prognostic significance has remained controversial so far. There is some evidence that high circulating ET-1 may be linked to poor outcomes in these patients [4], [9], [10], particularly in those at advanced stages of the disease [3], however, these associations have not been confirmed by all groups of researchers [6], [12], [13]. Unequivocal results of high plasma ET-1 levels and increased mortality in patients with CHF may be due to difficulties in the precise measurements of the rather unstable ET-1 in circulating blood (resulting from its short plasma half-life [14], its intermediate clearance by receptor binding in the pulmonary vascular bed [15], and its degradation by neutral endopeptidases [16], [17]. An alternative measure of the activity of the ET-1 system may be the assessment of circulating C-terminal pro-endothelin-1 (CT-proET-1), the C-terminal endothelin-1 precursor fragment, which is more stable than the active molecule and presumably inactive in the circulation [18], [19].
We hypothesized that measurement of plasma CT-proET-1 would carry additional prognostic value in a population of patients with CHF, beyond other generally accepted prognostic markers, including clinical measures of CHF severity and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP).
Methods
Study Population
We tested the aforementioned hypothesis in 491 patients with systolic CHF enrolled at 4 European centers: Verona (Italy, n = 230, 47%), Wroclaw (Poland, n = 122, 25%), London (United Kingdom, n = 80, 16%), and Athens (Greece, n = 59, 12%). The criteria for inclusion in our study were: 1) a ≥3 months documented history of CHF; 2) left ventricular ejection fraction (LVEF) ≤45% as assessed by echocardiography; 3) clinical stability and unchanged medications for at least one month preceding the study. The following exclusion criteria applied: a) revascularisation and/or acute coronary syndrome within 3 months preceding the study; b) circulatory decompensation within 1 month preceding the study; 3) lack of informed written consent. Inclusion and exclusion criteria were uniform in all participating centers.
In 11 additional cases (not included in the analyses), plasma CT-proET-1 levels were not available for technical reasons. Clinical characteristics of all studied patients are presented in Table 1. The study protocol was approved by the local ethics committee and all subjects gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki.
Plasma CT-proET-1 and NT-proBNP Measurements
In all patients with CHF, venous blood samples were taken in the morning following an overnight fast and after supine rest of at least 15 min. After centrifugation, plasma was collected and frozen at −80°C until being analysed. Plasma levels of CT-proET-1 (pmol/L) were assessed using a chemiluminescence sandwich immunoassay that used 2 polyclonal antibodies to amino acids 168–212 of pre-proET-1 (CT-proET-1 LIA, B.R.A.H.M.S GmbH, Hennigsdorf/Berlin, Germany) as previously described [16]. The analytical detection limit for plasma CT-proET-1 is 0.4 pmol/L. The interlaboratory variability coefficient is <10% for values >10 pmol/L [17], [18]. The stability of CT-proET-1 in plasma at room temperature is at least 4 hours [18].
Plasma levels of NT-proBNP (pg/mL) were determined by an electrochemiluminescence immunoassay on the Elecsys 1010/2010 System (Roche Diagnostics GmbH, Mannheim, Germany).
Clinical Follow-up
Patients were regularly seen by the study investigators with a follow-up duration of at least 12 months in all who survived. Information regarding survival was obtained directly from patients or their relatives, from the CHF clinic database, or from the hospital system. No patient was lost to follow-up. The primary end-point for the analysis was 12-month cardiovascular mortality. Cardiovascular mortality was defined as death due to myocardial infarction, sudden cardiac death, due to the progression of CHF, or death related to strokes.
Statistical Analyses
Continuous variables were expressed as mean ± standard deviation (SD). The inter-group differences were tested using Student's t-test, the χ2 test, or one-way ANOVA as appropriate. Plasma CT-proET-1, NT-proBNP and serum creatinine had skewed distributions and were therefore log10 transformed before analyses. They were expressed as medians with interquartile ranges (IQR). The inter-group differences were tested using the Mann-Whitney U test, the Pearson χ2 test, or the Kruskal-Wallis test as appropriate. Spearman's rank correlation and multivariable regression analyses using ordinary least squares were applied to establish variables plasma CT-proET-1 levels in patients with CHF.
The associations between analysed variables and survival were assessed using Cox proportional hazards analysis (both single predictor and multivariable models). In the multivariable analyses, we included age, New York Heart Association (NYHA) class, LVEF, and creatinine, as well as plasma levels of neurohormonal markers (CT-proET-1, NT-proBNP). NYHA class was included as a categorized variable. Due to the low number of patients in NYHA class I and a similar mortality rate in NYHA classes I and II, both groups were combined and were used as reference group. The assumptions of proportional hazards were tested for all the covariates. For continuous variables, hazard ratios (HR) per interquartile range (IQR) are reported (standardized HR). 95% confidence intervals (CI) for risk factors and significance levels for χ2 (Wald test) are given. The predictive value of each model was assessed by the model likelihood ratio χ2 statistic. In addition, to describe and compare the predictive performance of each multivariable model, the concordance index (c index) was calculated using a Harrel's method [19], [20]. To penalize over-fitting by entering multiple factors, the bootstrap-corrected version of the c index is given. Plasma levels of both CT-proET-1, NT-proBNP and serum creatinine were included in the model after log10 transformation.
In order to illustrate the effect of plasma CT-proET-1 on 12-month cardiovascular mortality rates, Kaplan-Meier curves for cumulative survival were constructed. For continuous variables, subsequent quartiles were used. Differences in survival rates were tested using the Cox-Mantel log-rank test. Receiver-operating characteristic (ROC) curves for prediction of 12-month mortality were constructed and the area under the curve (AUC) with a 95% confidence interval were calculated. To further contrast the prognostic accuracy of biomarkers, statistical comparison of ROC curves was performed using the method of paired ROC curves described by Hanley and McNeil [21]. A value of p<0.05 was considered statistically significant. Statistical analyses were performed using StatView 5.0 for Windows (Abacus Concepts, Berkley, CA) and R version 2.5.1 (http://www.r-project.org). All authors had full access to the data and took responsibility for the integrity and accuracy of the analyses.
Results
Plasma levels of CT-proET1 were evaluated in 491 patients with systolic CHF. For the additional 11 samples (all survivors), valid CT-proET-1 levels could not be determined due to a complete degradation. The median level of plasma CT-proET-1 was 63.6 pmol/L (IQR: 49.5–87.1 pmol/L).
Relationships Between Plasma CT-proET-1 and Clinical Variables in Patients with CHF
Median levels of plasma CT-proET-1 increased with increasing NYHA class (Figure 1). In single predictor regression analyses, plasma CT-proET-1 (log10) correlated positively with age (r = 0.33), serum creatinine (log10, r = 0.40) and plasma NT-proBNP (log10, r = 0.44, all p<0.0001). In single predictor regression analyses, plasma CT-proET-1 (log10) was inversely related to hemoglobin level (r = −0.26, p<0.0001), BMI (r = −0.12, p = 0.012) and LVEF (r = −0.15, p = 0.0013). Higher plasma CT-proET-1 levels were found in patients with ischemic CHF in comparison to subjects with non-ischemic CHF (p = 0.0002).
In a multivariable regression model based on all parameters included in univariate models, plasma CT-proET-1 (log10) was related significantly to NYHA class (r = 0.26, p<0.0001), serum creatinine (log10, r = 0.21, p<0.0001) and plasma NT-proBNP (log10, r = 0.13, p = 0.0009). The model explained 32.9% (adjusted R2) of total variance of plasma CT-proET-1 in patients with CHF.
Patients with CHF were divided into 4 subgroups according to ascending quartiles of plasma CT-proET-1, and clinical characteristics of these subgroups are presented in Table 2. Patients with CHF with the highest plasma CT-proET-1 (>upper quartile) had particularly high plasma NT-proBNP as compared to the 3 other subgroups and were characterised by unfavourable clinical features. Namely, they were older, had lower BMI, LVEF and hemoglobin levels, and higher NYHA class and serum creatinine levels. Moreover, they were more likely to have ischemic CHF (Table 2).
Survival Analyses
All survivors were clinically followed for up to 12 months. During follow-up there were 70 (14%) deaths, and 12- month mortality rate was 14%,. Mean time to death was 139±110 days (median: 116 days, range: 1–360 days). The proportionality assumption and the assumption of a log-linear relationship between the prognosticators and the hazard function were fulfilled for all tested variables.
Single Predictor Cox Regressions.
In single predictor Cox proportional-hazards models, the following variables were related to increased 12-month cardiovascular mortality in patients with CHF (Table 3): high plasma CT-proET-1 (standardized HR = 2.4, p<0.0001), high plasma NT-proBNP (standardized HR = 3.36, p<0.0001), advanced NYHA class (both when categorised into 3 and 4 groups, p<0.0001), high serum creatinine (standardized HR = 1.58, p = 0.0019), and the following variables were related to reduced 12-month cardiovascular mortality in this group of patients: high LVEF (HR = 0.32, p<0.0001), increased hemoglobin level (standardized HR = 0.60, p = 0.0006) and increased BMI (standardized HR = 0.652, p = 0.02), but neither age, sex nor CHF etiology (all p>0.1).
Twelve-month survival rates were 93% (95% CI: 86–96%), 93% (95% CI: 86–96%), 90% (95% CI: 83–93%) and 68% (95% CI: 58–75%) for those patients with plasma CT-proET-1 in ascending quartiles (Figure 2). Whilst patients with plasma CT-proET-1>87.1 pmol/L (upper quartile) had a particularly high 12-month mortality (32%) as compared to the 3 remaining subgroups (12-month mortality: approximately 7–10%) (Figure 2).
In receiver operating characteristic curve analysis, areas under curve for 12-month follow-up were similar for plasma CT-proET-1 and plasma NT-proBNP (AUC = 0.724 (CI 0.682–0.763) and 0.751 (CI 0.710–0.788), respectively; p>0.4).
Multivariable Cox Regressions.
In multivariable models that included LVEF, NYHA, age, NT-proBNP and creatinine, high plasma CT-proET-1 remained an independent predictor of increased 12-month cardiovascular mortality in patients with CHF (Table 3, p = 0.03). The higher the number of identified risk factors (plasma CT-proET-1>87.1 pmol/L [upper quartile], plasma NT-proBNP>2465 pg/mL [upper quartile], NYHA class III–IV, LVEF≤31% [median]), the worse the prognosis (risk factor model, Table 3).
Comparison of the Predictive value of CT-proET-1 and NT-proBNP.
The predictive values of different models were evaluated using the likelihood ratio χ2 statistic. A model adjusted for LVEF, age, serum creatinine, and NYHA class was defined as a base model. This model was compared with models including CT-proET-1, NT-proBNP or both biomarkers. Using the likelihood ratio χ2 test for nested models, CT-proET-1 and NT-proBNP were shown to add a significant prognostic value to the base model (p = 0.0003 and 0.004, respectively). CT-proET-1 added prognostic value to the base model including NT-proBNP (p = 0.02), and NT-proBNP added predictive value to a model that includes the variables of the base model plus CT-proET-1 (p = 0.045) (Table 4).
Discussion
Here we demonstrate that high plasma CT-proET-1 predicts increased 12-month cardiovascular mortality in patients with CHF, independently of clinical disease severity and plasma NT-proBNP.
The ET-1 system plays a crucial role in the pathophysiology of CHF [1], [2], [22]. Both vasoconstriction with unfavourable haemodynamic effects and cardiovascular remodelling contribute to the development and progression of CHF [1], [2], [22]. Recently, a new technique for the measurement of CT-proET-1, a stable ET-1 precursor fragment, has been developed [23]. CT-proET-1 has been used in several patient populations including patients with acute shortness of breath presenting to the emergency department [23], [24] and in stable outpatients with CHF [25], [26], [27]. Our study confirms and extends these studies, and we have demonstrated that plasma levels of CT-proET-1 are increased in patients with CHF as compared to values found in healthy controls in a previous study (mean: 44.3 pmol/L, range: 10.5–77.4 pmol/L) [28]. In patients with CHF, plasma CT-proET-1 correlates positively with disease severity (NYHA class). Moreover, patients with high plasma CT-proET-1 are older, have reduced hemoglobin levels and impaired renal function. These findings are analogous to the results obtained with regard to plasma ET-1 that were also increased in patients with CHF [3], [4], [9], [10], [11] and were positively associated with NYHA class [3], [9], [10], [11]. Similarly, big ET-1, a precursor of ET-1, is present in excess in the peripheral circulation in patients with CHF, particularly in advanced stages of disease [3], [27], [28]–[32].
So far, the prognostic value of plasma CT-proET-1 measurements has been proven only in patients during the acute phase of myocardial infarction [33], [34]. High plasma CT-proET-1 together with plasma NT-proBNP predicts an unfavourable outcome during the follow-up of 12 months [33]. In the current analyses, we have extended the prognostic applicability of plasma CT-proET-1 measurements to patients with systolic CHF, irrespective of etiology and disease severity. Some authors have demonstrated increased mortality in subjects with high plasma ET-1 in a whole population of patients with CHF [4], [9], [10] or in those with advanced CHF (NYHA III–IV) [3], but the other authors failed to confirm these associations [32], [33], [34]. However, all available data confirm the existence of relationships between high plasma big-ET-1 and poor outcome in patients with CHF [27], [28], [29], [31], also in those with severe CHF [3], [30], [32]. Therefore, we suggest that an assessment of ET-1 precursors (big ET-1 or CT-proET-1) rather than an active final molecule ET-1 may provide useful prognostic information in patients with CHF.
In some analyses, high plasma big ET-1 [27], [30], [32] or high plasma ET-1 [4], [9] was a better discriminator in predicting death in patients with CHF than plasma levels of natriuretic peptides, particularly in advanced stages of the disease [27], [30], . On the other hand, some workers have confirmed the superiority of circulating natriuretic peptides over plasma big ET-1 or ET-1 in survival analyses in patients with mild to moderate CHF [11], [13], [32] and severe CHF [11], [12], [28]. One limitation of the aforementioned studies may be the fact that relatively small groups of patients with CHF were examined. The most comprehensive analysis was performed in 2359 patients with CHF, enrolled in the Valsartan Heart Failure Trial (Val-HeFT) [29]. In this cohort, in multivariable survival analyses both plasma big ET-1 and plasma BNP (brain natriuretic peptide) were related to mortality, and combined mortality and morbidity (median follow-up: 23 months) [29]. Whilst plasma BNP was the stronger prognostic marker, the inclusion of plasma big ET-1 into the model increased the predictive power of the whole set of prognostic variables [29]. In the present analyses, plasma levels of both CT-proET-1 and NT-proBNP significantly and independently of each other predicted an increased 12-month cardiovascular mortality in patients with CHF, but the association between plasma CT-proET-1 and 12-month prognosis was stronger. Moreover, adding plasma CT-proET-1 to the base model had stronger prognostic power than adding plasma NT-proBNP. Finally, adding plasma CT-proET-1 to plasma NT-proBNP in this model provided further prognostic information.
Some limitations of this analysis deserve discussion. First, the study population consisted mainly of male patients, and it is unknown whether these findings can be directly extrapolated to female patients. Moreover, the number of patients in NYHA class I was relatively small (9%) and novel surrogate biomarkers usually perform better in high-risk populations than in low-risk subjects or unselected populations. Finally, the study group represents a population with a high risk of cardiovascular events. These facts have to be kept in mind when the data are being interpreted.
Author Contributions
Conceived and designed the experiments: EJ GSF SvH MC JCS PR BP WD WB OH JS AB SDA PP. Performed the experiments: EJ GSF SvH JP NM MC PR BP WD WB SDA PP. Analyzed the data: EJ GSF SvH MC PR BP WD WB SDA PP. Contributed reagents/materials/analysis tools: EJ GSF SvH JP NM MC PR BP WD WB OH JS AB SDA PP. Wrote the paper: EJ GSF SvH PR BP WD WB SDA PP.
References
- 1. Marasciulo FL, Montagnani M, Potenza MA (2006) Endothelin-1: the yin and yang on vascular function. Curr Med Chem 13: 1655–1665.
- 2. Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF (2006) Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111: 508–531.
- 3. Van Beneden R, Gurné O, Selvais PL, Ahn SA, Robert AR, et al. (2004) Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 10: 490–495.
- 4. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, et al. (1997) Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18: 254–258.
- 5. Swedberg K, Cleland J, Dargie H (2005) Guidlines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the ESC. Eur Heart J 26: 1115–1140.
- 6. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, et al. (2007) Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 50: 1973–1980.
- 7. Maisel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, et al. (2010) Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 55: 2062–2076.
- 8. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, et al. (2010) Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 12: 484–491.
- 9. Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, et al. (2000) Comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail 6: 201–207.
- 10. Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, et al. (1995) Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 76: 803–808.
- 11. Isnard R, Pousset F, Trochu J, Chafirovskaïa O, Carayon A, et al. (2000) Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 86: 417–421.
- 12. Gardner RS, Chong V, Morton I, McDonagh TA (2005) N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 7: 253–260.
- 13. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, et al. (1999) Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20: 1799–1807.
- 14. Weitzberg E, Ahlborg G, Lundberg JM (1991) Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 180: 1298–1303.
- 15. de Nucci G, Thomas R, D'Orleans-Juste P, Antunes E, Walder C, et al. (1988) Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 85: 9797–9800.
- 16. Ferro CJ, Spratt JC, Haynes WG, Webb DJ (1998) Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation 97: 2323–2330.
- 17. Rossi GP, Seccia TM, Albertin G, Pessina AC (2000) Measurement of endothelin: clinical and research use. Ann Clin Biochem 37: 608–626.
- 18. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 52: 1144–1151.
- 19. Struck J, Morgenthaler NG, Bergmann A (2005) Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides 26: 2482–2486.
- 20.
Harrell FE (2001) Regression modeling strategies. New York: Springer.
- 21. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves from the same cases. Radiology 148: 839–843.
- 22. Sugden PH, Clerk A (2005) Endothelin signalling in the cardiac myocyte and its pathophysiological relevance. Curr Vasc Pharmacol 3: 343–351.
- 23. Adlbrecht C, Hülsmann M, Strunk G, Berger R, Mörtl D, et al. (2009) Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 11: 361–366.
- 24. Dieplinger B, Gegenhuber A, Kaar G, Poelz W, Haltmayer M, et al. (2010) Prognostic value of established and novel biomarkers in patients with shortness of breath attending an emergency department. Clin Biochem 43: 714–719.
- 25. Masson S, Latini R, Carbonieri E, Moretti L, Rossi MG, et al. (2010) The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail 12: 338–347.
- 26. Adlbrecht C, Hülsmann M, Strunk G, Berger R, Mörtl D, et al. (2009) Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients. Eur J Heart Fail 11: 361–366.
- 27. Stanek B, Frey B, Hülsmann M, Koller-Strametz J, Hartter E, et al. (1997) Validation of big endothelin plasma levels compared with established neurohumoral markers in patients with severe chronic heart failure. Transplant Proc 29: 595–596.
- 28. Stanek B, Frey B, Hülsmann M, Berger R, Sturm B, et al. (2001) Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38: 436–442.
- 29. Masson S, Latini R, Anand IS, Barlera S, Judd D, et al. (2006) The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 12: 375–380.
- 30. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, et al. (1996) Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27: 633–641.
- 31. Hülsmann M, Stanek B, Frey B, Sturm B, Putz D, et al. (1998) Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 32: 1695–1700.
- 32. Berger R, Strecker K, Huelsmann M, Moser P, Frey B, et al. (2003) Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. J Heart Lung Transplant 22: 1037–1045.
- 33. Khan SQ, Dhillon O, Struck J, Quinn P, Morgenthaler NG, et al. (2007) C-terminal pro-endothelin-1 offers additional prognostic information in patients after acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Am Heart J 154: 736–742.
- 34. Behnes M, Papassotiriou J, Walter T, Fiedler E, Sauer T, et al. (2008) Long-term prognostic value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction. Clin Chem Lab Med 46: 204–211.